A randomized double-blind, placebo-controlled pilot trial of heat-killed Bifidobacterium bifidum OLB6378 concentrate on fecal IgA levels in children and their parents
Abstract Objective This pilot study aimed to evaluate the effect of dietary heat-killed Bifidobacterium bifidum OLB6378 concentrate (OLB6378 concentrate) on gut IgA production during childhood and beyond. Results This study was designed as a randomized, double-blind, placebo-controlled pilot trial for children and their parents. After 2-week intake of placebo or OLB6378 drink, an overall analysis with a mixed model for repeated measures showed no significant difference in fecal IgA levels between the groups for children and parents (placebo vs. active: n = 18 vs. n = 15 in children, n = 18 vs. n = 17 in parents). The estimated effect sizes for the change in fecal IgA levels at week 2 were d = 0.32 (95% confidence interval [CI] = − 0.37–1.01) in children and d = − 0.19 (95% CI = − 0.85–0.48) in parents. In conclusion, 2-week supplementation with OLB6378 concentrate did not significantly increase fecal IgA levels in children or parents, although the study provided preliminary feasibility information for designing a future confirmatory trial in children. These findings are hypothesis-generating and provide preliminary data to determine parameter variance and sample size calculations for future larger-scale trials.
Authors
- Keigo Sato (ORCID: https://orcid.org/0000-0002-1209-1179)
- Shinji Jinno (ORCID: https://orcid.org/0000-0002-1971-4631)
- Megumu Igawa
- Chiharu Tsutsumi
Institutions
- Meiji (Japan) (JP)
- Sagami Women's University (JP)
Publication Details
- Journal
- BMC Research Notes
- Published
- 2026-11-12
- DOI
- https://doi.org/10.1186/s13104-026-08095-9
- Primary Topic
- Probiotics and Fermented Foods
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Food Science Institute Foundation